Green tea extract after chemotherapy for extensive small cell lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests whether taking a green tea extract pill can help people with extensive-stage small cell lung cancer after their first chemotherapy. It aims to see if the extract can keep the cancer from growing, or help you feel better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been diagnosed with small cell lung cancer that has spread widely (extensive stage).
- You must have completed your first round of chemotherapy, and the cancer has not gotten worse.
- You should be generally able to care for yourself (performance status 0 to 2).
- You must be at least 18 years old.
- Your blood counts (white cells, platelets, hemoglobin), kidney function, and liver function need to be within a certain range.
- You should not have had 5 or more cups of green tea per day in the week before starting the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of two chemotherapy drugs (irinotecan liposome and a platinum drug) plus an immunotherapy drug and a targeted therapy (anlotinib) as maintenance treatment after initial chemotherapy for extensive-stage small cell lung cancer. The goal is to see if this combination keeps the cancer from growing for as long as possible.
This trial tests a combination of two experimental immunotherapy drugs (ivonescimab and cadonilimab) with standard chemotherapy for people with extensive-stage small cell lung cancer who have not had prior treatment. The goal is to see if this combination works better than chemo alone.
This trial tests a combination of drugs as a maintenance therapy after initial chemotherapy for extensive-stage small cell lung cancer. It aims to see if this combination can help keep the cancer from growing.
This trial looks at whether giving additional targeted radiation to the chest can help people with extensive-stage small cell lung cancer after they finish standard chemo-immunotherapy. It may help control the cancer in the lung area and prevent it from coming back there.
This trial tests a combination of low-dose radiation to the chest, immunotherapy (adebrelimab), and chemotherapy for extensive-stage small cell lung cancer. The goal is to see if this approach can help control the cancer better than standard treatments and potentially improve outcomes.
This trial tests a combination of an immunotherapy drug (tislelizumab) with chemotherapy and chest radiation for people with extensive-stage small cell lung cancer (SCLC) that has spread. The goal is to see if this combination helps shrink or control the cancer longer.
Hear when a new Small Cell Lung Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.